CMS Open Payments · Program Year 2024
Genmab U.S., Inc.
Genmab U.S., Inc. reported $16,486,403.76 in payments to 8,227 physicians and teaching hospitals across 9,142 transactions.
- $16.5M
- Total payments
- 9,142
- Transactions
- 8,227
- Recipients
- +$966.6K
- General Payments vs PY2023
Genmab U.S., Inc. reported $16,486,403.76 in payments to 8,227 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #114 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $2.0K per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
The verdict
Genmab U.S., Inc. pairs top-10% payment volume with an unusually diversified payment pattern across a wide recipient base.
- #114
- of 1,925 companies
- 0.1%
- of all US industry payments
- 0.1%
- paid to its single top recipient
- 7
- payment categories
Release-over-release change
General Payments changed from PY2023 to PY2024
Genmab U.S., Inc.'s CMS-reported General Payments increased by $966.6K (+85.1%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.
CMS source labels for this exact identifier: PY2022: GENMAB U.S., INC.PY2023: GENMAB U.S., INC.PY2024: Genmab U.S., Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,135,426.38
- PY2024
- $2,101,978.92
How Genmab U.S., Inc. ranks nationally
Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.
Genmab U.S., Inc.'s total vs. every reporting company
CMS Open Payments, Program Year 2024
$16,486,404 Top 6% higher than 94% of 1,925 reporting companies
Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Open Payments · 2024
What the Data Shows for Genmab U.S., Inc.
Averaging $1.8K per transaction and $2.0K per recipient, Genmab U.S., Inc.'s Program Year 2024 total comes to $16,486,403.76 across 9,142 transactions and 8,227 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #114 of 1,925 companies, representing 0.1% of all industry payments reported nationwide for the year.
212 transactions worth $702.2K make "Compensation for Services Other Than Consulting" the top general-payment category in the 7-category breakdown below, 4.3% of the reported total (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Genmab U.S., Inc.'s 7-category general-payment breakdown at $702.2K, 4.3% of the reported total.
How Genmab U.S., Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $702.2K | 212 | 4.3% |
| Consulting Fee | $484.6K | 172 | 2.9% |
| Travel and Lodging | $299.6K | 585 | 1.8% |
| Food and Beverage | $258.0K | 7,220 | 1.6% |
| Education | $160.5K | 3 | 1.0% |
| Space Rental or Facility Fees | $122.0K | 34 | 0.7% |
| Grant | $75.0K | 1 | 0.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $393,702.17 (18.7%) of $2,101,978.92 in this company's General Payments records across 4,410 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Genmab U.S., Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Montefiore Medical Center
$150,000.00 across 1 reported transactions
- 2
Bradley Monk
$78,284.89 across 58 reported transactions
- 3
University Of Washington Med Ctr
$75,000.00 across 1 reported transactions
- 4
Tara Graff
$45,788.28 across 33 reported transactions
- 5
Heidi Godoy
$44,629.00 across 22 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Payment Size Analysis
Average transaction size: $1.8K. Average per recipient: $2.0K.
Total Amount
$16,486,403.76
Avg per Transaction
$1.8K
Avg per Recipient
$2.0K
Payment Transparency Context
What is the Sunshine Act?
The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.
Industry Total (2024)
$13.9B
across 1,925 companies
Genmab U.S., Inc. Share
0.1%
#114 by total payments
Companies with Similar Payment Volumes
Pharmaceutical companies with payment totals similar to Genmab U.S., Inc.
Frequently Asked Questions
How much did Genmab U.S., Inc. pay to physicians and hospitals in 2024? ▾
How many physicians received payments from Genmab U.S., Inc.? ▾
What types of payments did Genmab U.S., Inc. make? ▾
How does Genmab U.S., Inc. rank among pharmaceutical companies? ▾
What is the average payment size from Genmab U.S., Inc.? ▾
Where does the payment data for Genmab U.S., Inc. come from? ▾
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.